Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Check source scope before reading a dose
Alyq - labeled renal guidance
Product / population
Tadalafil (Alyq), adult oral tablets for pulmonary arterial hypertension
Renal method
Creatinine clearance (CrCl), mL/min; use the product-specific calculation
Source revision
DailyMed SPL version 6, effective 2023-04-01; posted Aug 20, 2026
All record notes are retained here, including notes about sources not selected in this review.
Alyq - product and source limitations
The cited PAH table does not assign exactly 30 mL/min to either adjacent band. Keep this boundary open and verify with the prescribing team.
What to reconcile: The cited PAH table does not assign exactly 30 mL/min to either adjacent band. Keep this boundary open and verify with the prescribing team.
At CrCl 31-80 mL/min, start at 20 mg once daily and consider 40 mg once daily if tolerated. Avoid use in severe impairment or on hemodialysis. The renal table lists moderate impairment as 31-50 and severe as below 30. At exactly 30, verify the intended band with the prescribing team.
RDM73-alyq-official-1 · Source locator: Renal guidance: 2.2 and 8.6
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh Renal Dosing Master v7.4. Review the retrieval and revision dates attached to each source. Selecting a reference does not imply clinical verification.
